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OBJECTIVES The aim of this study was to evaluate the immediate and long-term outcome of intracoronary
stent implantation for the treatment of coronary artery bifurcation lesions.
BACKGROUND Balloon angioplasty of true coronary bifurcation lesions is associated with a lower success and
higher complication rate than most other lesion types.
METHODS We treated 131 patients with bifurcation lesions with $1 stent. Patients were divided into
two groups; Group (Gp) 1 included 77 patients treated with a stent in one branch and
percutaneous transluminal coronary angioplasty (PTCA) (with or without atherectomy) in
the side branch, and Gp 2 included 54 patients who underwent stent deployment in both
branches. The Gp 2 patients were subsequently divided into two subgroups depending on the
technique of stent deployment. The Gp 2a included 19 patients who underwent Y-stenting,
and Gp 2b included 33 patients who underwent T-stenting.
RESULTS There were no significant differences between the groups in terms of age, gender, frequency
of prior myocardial infarction (MI) or coronary artery bypass grafting (CABG), or vessels
treated. Procedural success rates were excellent (89.5 to 97.4%). After one-year follow-up, no
significant differences were seen in the frequency of major adverse events (death, MI, or repeat
revascularization) between Gp 1 and Gp 2. Adverse cardiac events were higher with
Y-stenting compared with T-stenting (86.3% vs. 30.4%, p 5 0.004).
CONCLUSIONS Stenting of bifurcation lesions can be achieved with a high success rate. However, stenting of
both branches offers no advantage over stenting one branch and performing balloon
angioplasty of the other branch. (J Am Coll Cardiol 2000;35:929–36) © 2000 by the
American College of Cardiology
Coronary artery bifurcation lesions are difficult to treat with
conventional balloon angioplasty and are associated with
both a low success rate and relatively high incidence of
procedural complications, including myocardial infarction
(MI) and emergency coronary artery bypass grafting
(CABG) (1,2). Various balloon and guide wire techniques
have been applied, including “kissing” (simultaneous) and
sequential balloon inflations (3–5). More recently, debulk-
ing techniques such as directional (6–11) and rotational
atherectomy (12) have been evaluated for the treatment of
these lesions. The practice of stent implantation for these
lesions has evolved significantly in recent years, and different
practical approaches have been suggested, including “T-
stenting,” “reverse Y-stenting,” “trouser-leg stenting,” and
stent implantation of the major branch with percutaneous
transluminal coronary angioplasty (PTCA) or debulking of
the side branch (13–22). To date, however, it is uncertain
how these approaches compare with one another regarding
in-hospital and long-term outcomes. Thus, the purpose of
this study was to analyze the immediate and longer-term
outcomes of patients treated with these different approaches
involving intracoronary stent implantation in coronary ar-
tery bifurcation lesions at our institution.
METHODS
Patient population. We performed an analysis of the
Mayo Clinic PTCA database and reviewed all coronary
interventional procedures performed at our institution be-
tween October 1993 and November 1998. This prospec-
tively coded registry includes baseline demographic, clinical,
and angiographic data. Included were all patients with true
bifurcation lesions, defined as lesions in which there was a
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.50% diameter stenosis in both the parent vessel and the
ostium of a side branch arising from the lesion, and both
were .2.0 mm in diameter by visual estimation. These are
class D and F bifurcation lesions according to the Duke
classification scheme (23). Patients who presented with
recent MI (defined as MI within 24 h of the index
procedure) or cardiogenic shock were excluded (n 5 16).
This study was approved by the Institutional Review Board
at the Mayo Clinic. Informed consent was obtained from all
patients for the release of all such information.
Procedure. All patients were treated between October
1993 and November 1998 (2 in 1993; 2 in 1994; 11 in 1995;
21 in 1996; 34 in 1997; 61 in 1998). All patients received
preprocedural oral aspirin (325 mg) and aspirin 81 to
325 mg daily thereafter. Until 1994, patients undergoing
stent implantation received dextran immediately before the
procedure in accordance with the stent manufacturer’s
instructions, warfarin (target International Normalized Ra-
tio of 2.0 to 4.0), and dipyridamole 75 mg three times daily.
From late 1994 through 1995, warfarin was administered
only to patients with suboptimal stent deployment as
assessed by coronary angiography or intravascular ultra-
sound or to the presence of risk factors associated with an
increased risk of stent thrombosis. Dipyridamole was not
used after 1994.
Beginning late 1995, warfarin was administered to pa-
tients only if clinically indicated for reasons unrelated to
stent implantation. All other patients were treated with
ticlopidine 250 mg twice daily (initially for four to six weeks
and, from mid-1996, for two weeks). From March 1998 to
the present, clopidogrel 300 mg oral load, followed by
75 mg daily for 14 days, was used in place of ticlopidine.
Beginning late 1995, subcutaneous enoxaparin (30 to 60 mg
twice daily) (Lovenox, Rhone-Poulenc-Rorer, Collegeville,
Pennsylvania) was administered subcutaneously for 10 to 14
days to patients believed to be at increased risk of stent
thrombosis; at the operator’s discretion, this was infre-
quently used.
Patients were divided into two groups; Group (Gp) 1
(n 5 77) included patients who were treated with a stent in
one branch and balloon angioplasty with or without
atherectomy in the other branch. Group (Gp) 2 (n 5 54)
consisted of patients who underwent stent implantation in
both branches. Group 2 was further divided into two
subgroups depending on the stent deployment technique;
Gp 2a (n 5 19) consisted of patients in whom reverse
Y-stenting technique was used, and Gp 2b (n 5 33)
included patients who underwent T-stenting (Fig. 1). Two
patients underwent treatment using a third approach, the
“trouser-leg stenting” and hence were excluded from this
subanalysis.
The type of stenting technique used was at the discretion
of the attending interventional cardiologist. The T-shaped
stent approach consisted of implanting the proximal edge of
the stent in the side branch abutting with the body of the
stent inserted in the major vessel. The ostial side branch
stent was placed first in the majority of cases. Then, the wire
in this branch was removed and the second stent was
implanted in the major artery spanning the origin of the
branch vessel. For the Y-stent procedure, the first stent was
generally deployed into the branch with the more severe
angle. The guide wire was removed and placed in the other
branch, exiting the mid-portion of the first stent. A balloon
was inflated to spread the stent struts, allowing passage of a
second stent in the artery through the first one as previously
described (21), with the proximal portion of both stents
overlapping one another. Additional balloon inflations were
made in the first stent placed, and in many cases simulta-
neous inflations in both stents were performed.
First-generation stents utilized included Palmaz-Schatz
stent (SDS; Johnson & Johnson Interventional Systems,
Miami, Florida) and the Gianturco-Roubin I (Cook,
Bloomington, Indiana). Second-generation stents used in
the study included the Multilink stent (Advanced Cardio-
vascular Systems), the AVE Micro stent (Arterial Vascular
Engineering, Santa Rosa, California), the NIR stent (Medi-
nol, Natick, Massachusetts), Gianturco-Roubin II (Cook,
Bloomington), and Crown (Cordis, Miami, Florida).
Follow-up angiography was usually performed only in
patients with recurrent symptoms or signs suggestive of
myocardial ischemia. The patient’s attending physician
determined whether to refer the patient for an additional
coronary revascularization and, if so, whether it would be a
repeat percutaneous coronary revascularization procedure or
coronary artery bypass surgery.
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CCS 5 Canadian Cardiovascular Society
CK 5 creatine kinase
Gp 5 group
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
Figure 1. Techniques of stenting both arms of a bifurcation lesion.
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Angiography and ventriculography. The severity of cor-
onary artery disease was assessed visually, generally by two
observers, using two orthogonal views. Either sublingual
nitroglycerin (0.4 mg), intracoronary nitroglycerin (100 to
200 mg) or both were given before the initial and final
angiographic assessment. Single-vessel coronary artery dis-
ease was defined as luminal diameter stenosis of $70% of
one major epicardial artery. Two- or three-vessel disease
was diagnosed if there were one or two additional major
epicardial arteries with at least a 70% luminal diameter
stenosis, respectively.
The left ventricular ejection fraction was determined by
ventriculography at the time of diagnostic angiography or
during follow-up, as indicated clinically, by echocardiogra-
phy, a radionuclide study, or left ventriculography.
Definitions. Procedural Q-wave MI was defined as the
presence of new Q waves on the electrocardiogram (ECG)
with either serum creatine kinase (CK), MB fraction con-
centrations that were at least three times higher than normal
or positive tests for MB isoenzymes, an episode of pro-
longed angina, or new regional wall-motion abnormalities
in the area of the treated vessel.
Complete revascularization was defined as successful
dilation of all stenoses $70%. Incomplete revascularization
was defined as a $70% diameter stenosis of one or more
remaining arteries.
A successful procedure was defined as a $20% reduction
in the stenosis of the lesions treated, resulting in a residual
stenosis of ,50% of the luminal diameter. Clinical success
was defined as the achievement of angiographic success
without in-hospital death, Q-wave MI, or referral for
CABG.
Death from cardiac causes was defined as death due to
MI, sudden death not proven to be noncardiac in nature,
heart failure, or complications of cardiac surgery or trans-
plantation.
Follow-up. Patients were contacted six and 12 months
after the procedure and yearly thereafter by research tech-
nicians using a standardized questionnaire. In addition, if
patients were rehospitalized during the follow-up period,
the medical records of admissions and treatments at the
Mayo Clinic and elsewhere were reviewed and data ex-
tracted, verified, and recorded. Follow-up angiography was
generally only performed for clinical indications at the
discretion of the attending physician, such as the recurrence
of severe angina or for an early positive functional test.
Major adverse clinical events during the follow-up period
included death, MI, (Q-wave and non-Q-wave), and severe
angina (Canadian Cardiovascular Society [CCS] class III or
IV). The frequency rates of repeat coronary angioplasty and
coronary artery bypass surgery were also analyzed.
End points. The primary end point of this study was to
evaluate procedural success and complication rates for the
treatment of bifurcation lesions with one or more stents. We
also sought the frequency of adverse cardiac events during
one year of follow-up.
Statistical analysis. Comparisons of the baseline variables
were done with the Student t test for continuous data or
Pearson’s chi-square test for discrete data. Event-free sur-
vival curves were calculated using the Kaplan-Meier meth-
od; differences between the groups were tested with the
log-rank test statistic. Univariate Cox proportional hazard
survival models were fit to calculate the relative risk of an
event for abciximab and debulking; other baseline variables
were also looked at univariately. Multivariate models were
constructed, but because of the low number of events we
found nothing significant.
RESULTS
Of the 325 patients in our database who underwent coro-
nary stenting of a major vessel and a branch arising from
that vessel, 147 patients with true bifurcation lesions were
identified. Sixteen patients were excluded because they had
a MI #within 24 h of the procedure or had cardiogenic
shock. The remaining 131 patients constitute the study group.
The outcome of the study group was initially compared to
patients who underwent balloon angioplasty alone. Overall
lesion success (98.1% vs. 89.5%, p , 0.05) and procedural
success (93% vs. 80%, p , 0.05) were significantly higher in
patients who underwent intracoronary stent implantation
when compared to balloon angioplasty alone.
Patient characteristics. There were no significant differ-
ences in age, gender, risk factors, frequency of prior MI or
previous CABG or the indications for revascularization
between the various groups as shown in Table 1.
Angiographic characteristics and procedural perfor-
mance. Among the 77 patients in Gp 1 who underwent
stent deployment in one vessel, 55 (71%) underwent balloon
angioplasty alone in the side branch and 22 (29%) under-
went combination of balloon angioplasty with atherectomy.
Among the 54 patients who underwent stent deployment in
both branches, 47 (87%) underwent adjunctive balloon
angioplasty and 7 (13%) underwent combination of balloon
angioplasty with atherectomy prior to stent deployment. Of
those patients who underwent stent deployment in both
arms, 19 (37%) patients underwent Y-stenting and 33 (64%)
underwent T-stenting (Fig. 2). There were no significant
differences in the angiographic characteristics between the
two study groups as shown in Table 2.
The mean maximum balloon sizes used for the main
branches of the various groups were similar (3.4 6 0.4 mm
in Gp 1, 3.4 6 0.4 mm in Gp 2, 3.3 6 0.4 mm in Gp 2a,
and 3.5 6 0.5 mm in Gp 2b), and they were in the side
branches as well (2.9 6 0.4 in Gp 1, 3.0 6 0.4 mm in Gp
2, 3.1 6 0.5 mm in Gp 2a, and 3.0 6 0.2 mm in Gp 2b).
The mean stent sizes used for the treatment of the main
branches were also similar (3.2 6 0.4 mm in Gp 1, 3.0 6
0.4 mm in Gp 2, 3.1 6 0.5 mm in Gp 2a, and 3.0 6 0.0 mm
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in Gp 2b) and for the side branches as well (3.2 6 0.4 in Gp
2, 3.3 6 0.4 mm in Gp 2a, and 3.0 6 0.3 mm in Gp 2b).
The angiographic success rate was high in all the study
groups, regardless of which approach was used (97.4% Gp 1
vs. 94.4% Gp 2, p 5 0.38). When procedural complications
were analyzed according to the approach used, the incidence
of major complication rates was relatively low and no
significant differences were seen between those who under-
went stent implantation in one branch versus both branches
with regards to death, Q-wave MI, or the need for emer-
gency CABG.
Further analysis of the angiographic characteristics and
complication rates in patients who underwent stent deploy-
ment in both arteries according to the stent approach are
shown in Table 2. Procedural success rate tended to be
greater in those who underwent T- rather than the
Y-shaped stent design; however, this difference was not
statistically significant (89.5% in Gp 2a vs. 97.0% in Gp 2b,
p 5 0.26). The frequency rates of death, QMI, and the need
for emergency CABG were relatively low, and no significant
differences existed among the various groups.
Multivariate analysis was performed to ascertain whether
the selection of stenting technique was associated with
certain variables including the clinical presentation of pa-
tients, angiographic characteristics including the severity of
vessel tortuosity, straightness of the vessel, the presence of
thrombus, calcification, eccentricity of the treated lesions,
balloon and stent size, transient occlusion of the main or
side branch, and the development of chest pain or hypoten-
sion during the procedure. None of these variables were
associated with the use of a particular stenting technique.
Late clinical results. After one year of follow-up, no
significant differences were noted in survival or the occur-
rence of MI, CABG, or need for repeat revascularization
between those who underwent stent implantation in only
one artery versus those who underwent stent implantation in
both arteries (Table 3). Patients who underwent stent
deployment in both arteries tended to develop more severe
angina (19.4% in Gp 1 vs. 39.5% in Gp 2, p 5 0.12) and
require revascularization compared with those who under-
went stent deployment in one arm only (17.4% in Gp 1 vs.
19.4% in Gp 2, p 5 0.59 and CABG; 3.7% in Gp 1 vs. 7.5%
in Gp 2, p 5 0.41), although these differences did not reach
statistical significance (Table 3). There was a trend toward
better long-term outcome in Gp 1 versus Gp 2 (Fig. 3).
Further analysis of Gp 2 according to the treatment
approach is shown in Table 3. No significant differences
were seen between the two groups with regards to mortality
or the occurrence of MI. However, at one year, the
incidence of severe angina was 69% in patients who under-
went Y-stent deployment versus 23.9% in the T-stent group
Table 1. Baseline Clinical Characteristics of the Study Population
Characteristic
Group 1
(n 5 77)
Group 2
(n 5 54)
Group 2a
(n 5 19)
Group 2b
(n 5 33)
Age, yrs (mean 6 SD) 63.0 6 11.3 64.0 6 12.4 60.8 6 10.6 66.5 6 13.0
Men 56 (72.7) 40 (74.1) 14 (73.7) 24 (72.7)
CCS classification
III 24 (36.9) 14 (29.2) 7 (43.8) 7 (21.0)
IV 20 (30.8) 15 (31.3) 5 (31.3) 10 (32.3)
Congestive heart failure 8 (10.5) 2 (3.7) 1 (5.3) 1 (3.0)
Ejection fraction, % (mean 6 SD) 62.6 6 14.0 60.8 6 14.1 63.0 6 15.9 58.3 6 11.9
Current smoker 16 (21.1) 8 (14.8) 3 (15.8) 4 (12.1)
Diabetes mellitus 15 (19.5) 10 (18.5) 3 (15.8) 6 (18.2)
Hypertension 44 (57.9) 32 (59.3) 13 (68.4) 19 (57.6)
Hypercholesterolemia 49 (66.2) 35 (68.6) 12 (63.2) 22 (73.3)
Family history of CAD 16 (27.6) 12 (27.3) 2 (13.3) 9 (33.3)
Prior myocardial infarction 32 (41.6) 21 (40.4) 6 (35.3) 14 (42.4)
Prior coronary artery bypass surgery 9 (11.7) 8 (14.8) 3 (15.8) 5 (15.2)
Data presented are numbers (%) of patients, unless otherwise indicated. CCS 5 Canadian Cardiovascular Society.
Group 1 included patients who underwent stent deployment in one vessel; Group 2 included patients who received stent
deployment in both vessels; Group 2a patients underwent treatment with Y-stent approach; and Group 2b underwent treatment
with a T-stent approach.
Figure 2. Flow diagram demonstrating the different stenting
procedures used in the study population.
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(p 5 0.006). Group 1 and Gp 2 patients who underwent
target lesion revascularization all received treatment of the
side branch, and 80% also received treatment of the main
branch. In the Y-stent group, three side branches were
completely occluded at follow-up. The cumulative occur-
rence of mortality, MI, severe angina, and need for repeat
procedure was significantly greater in the Y-stent group
than in the T-stent group, as shown in Figure 4.
The use of atherectomy or abciximab was not associated
with a significant improvement in outcome (atherectomy
RR 0.78 [CI 95%: 0.34, 1.81, p 5 0.56], abciximab RR 0.86
[CI 95%: 0.43, 1.70, p 5 0.67]).
DISCUSSION
This study demonstrates that percutaneous coronary inter-
ventions in bifurcation lesions with coronary stents overall
are associated with high procedural success and low acute
complication rates independent of whether stents were
deployed in one or both vessels. In addition, after one year
of follow-up, the frequency of death or MI was relatively
low among the various groups. However, severe angina and
revascularization tended to occur more frequently in the
group that underwent stent deployment in both vessels, in
particular in those who underwent Y-stenting. This study
suggests that treatment of true bifurcation lesions with
stents in both vessels may not offer any advantage over
stenting of one vessel and balloon angioplasty and or
atherectomy of the other.
The treatment of bifurcation lesions has posed a signifi-
cant challenge to interventional cardiologists over the years
and has been associated with relatively frequent procedural
complications including MI and emergency coronary bypass
surgery (1,2). Recently, however, considerable progress has
been made in the field of percutaneous coronary revascular-
Table 2. Angiographic Characteristics, Outcome and Adverse Procedural Outcomes of the Study
Population
Characteristic
Group 1
(n 5 77)
Group 2
(n 5 54)
Group 2a
(n 5 19)
Group 2b
(n 5 33)
De novo lesions 72 50 17 31
Restenotic lesions 5 4 2 2
Atherectomy 21 (27)* 7 (13) 3 (16) 4 (12)
Abciximab 36 (47) 24 (44) 9 (47) 15 (45)
Ticlopidine or clopidogrel 66 (86) 50 (94) 18 (95) 30 (91)
Location
LAD/Diagonal 54 (71) 27 (50) 8 (42) 18 (55)
Circumflex/Obtuse marginal 10 (13) 15 (28) 4 (21) 10 (30)
Right coronary artery/PDA/PLA 12 (16) 12 (22) 7 (37) 5 (15)
Extent of disease
Single vessel 39 (52.7) 25 (51.0) 7 (41.2) 18 (58.1)
Double vessel 29 (39.2) 15 (30.6) 7 (41.2) 7 (22.6)
Triple vessel 6 (8.1) 9 (18.4) 3 (17.6) 6 (19.4)
Lesion characteristics
Thrombus 17 (22) 6 (19) 4 (15) 2 (12)
Calcification 39 (54) 22 (49) 8 (42) 12 (36)
Tortuosity 36 (48) 36 (55) 12 (67) 23 (74)
Eccentricity 61 (90) 43 (84) 15 (88) 26 (81)
Stent type
Palmaz-Schatz (13) (22) (0) (21)
Giantruco-Roubin I (23) (16) (4) (21)
Giantruco-Roubin II (6) (6) (4) (8)
Wiktor (4) (3) (0) (5)
Crown (5) (0) (0) (0)
AVE (15) (32) (59) (8)
ACS (29) (14) (22) (21)
NIR (1) (2) (0) (3)
Other (4) (5) (11) (13)
Angiographic success 75 (97.4) 51 (94.4) 17 (89.5) 32 (97.0)
Complications
QMI 1 (1.3) 1 (1.9) 1 (5.3) 0 (0.0)
CABG 0 (0.0) 1 (1.9) 1 (5.3) 0 (0.0)
Death 1 (1.3) 1 (1.9) 0 (0.0) 1 (3.0)
Data presented are numbers (%) of patients, unless otherwise indicated. CCS 5 Canadian Cardiovascular Society; LAD 5 left
anterior descending artery; PDA 5 posterior descending artery; PLA 5 posterolateral artery; CABG 5 coronary artery bypass
graft; QMI 5 Q-wave myocardial infarction. *p , 0.05 group 1 versus group 2.
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ization. Procedural techniques other than balloon angio-
plasty have been developed. The feasibility of rotational
atherectomy with adjunctive balloon angioplasty and stent-
ing in the treatment of bifurcation lesions in 15 patients has
recently been reported, with high procedural success rates
and low complication rates (12). In addition, Dauerman et
al. (7) reported their experience with atherectomy in the
treatment of true bifurcation lesions. They compared con-
ventional balloon angioplasty using a double-wire technique
in which simultaneous (“kissing”) or sequential balloon
inflations to debulking, primarily using directional atherec-
tomy, followed by adjunctive balloon angioplasty. These
investigators observed significantly lower postprocedural
residual stenoses and a significantly lower target vessel
revascularization rate at follow-up in the debulking group
compared with the balloon angioplasty group. Whether
these results can be reproduced by other centers remains to
be determined (24).
Another recent advance in the treatment of bifurcation
lesions is the use of coronary stents (25). The widespread
use of stents is based on a number of randomized controlled
trials confirming their superior long-term results compared
with balloon angioplasty (26–28). However, none of these
studies permitted treatment of bifurcation lesions. Intra-
coronary stent implantation across side branches is associ-
ated with an increased risk of side branch occlusion as well
as restriction of future access to the side branch. These
concerns have limited their use in bifurcation lesions
(29,30).
Previous studies of stenting across bifurcation lesions.
Data on the role of stenting for the treatment of bifurcation
lesions are limited to a number of case reports, small series
(12–22), and preliminary studies (31–34) describing various
techniques (T-stenting, reverse Y-stenting, and trouser-leg
stenting). Carrie et al. (21) reported their experience of
stenting bifurcation lesions in 54 patients using either T- or
reverse Y-stenting techniques, and they demonstrated that
the procedural success rate was high regardless of which
approach was used. Our study and other preliminary studies
suggest that stenting of bifurcation lesions can be achieved
with a high success rate and an acceptable complication rate,
Figure 3. Kaplan-Meier curves of the probability of survival and
freedom from myocardial infarction (MI), bypass surgery, and
repeat coronary angioplasty and severe angina (CCS class III or
IV) in the two treatment groups.
Figure 4. Kaplan-Meier curves of the probability of survival and
freedom from myocardial infarction (MI), bypass surgery, and
repeat coronary angioplasty and severe angina (CCS class III or
IV) in Gp 2a and Gp 2b.
Table 3. Adverse Cardiac Events at One Year
Characteristic
Group 1
(n 5 75)
Group 2
(n 5 51)
Group 2a
(n 5 17)
Group 2b
(n 5 32)
Severe angina (CCS III–IV) 10 (19.4) 14 (39.5) 9 (69.1)* 5 (23.9)
QMI 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any MI 0 (0.0) 1 (2.4) 0 (0.0) 1 (4.2)
Repeat procedure 9 (17.4) 8 (19.4) 5 (33.3) 3 (12.5)
TLR 11 (20.5) 8 (19.4) 5 (33.3) 3 (12.5)
CABG 2 (3.7) 3 (7.5) 2 (14.3) 1 (3.8)
Death 1 (2.1) 3 (8.8) 1 (14.3) 2 (8.2)
Any of these events 14 (26.8) 18 (47.7) 11 (86.3)† 7 (30.4)
Data presented are numbers (%) of patients, unless otherwise indicated. CCS 5 Canadian Cardiovascular Society Classification;
CABG 5 coronary artery bypass graft; MI 5 myocardial infarction; TLR 5 Target lesion revascularization. *p 5 0.006 group
2a versus group 2b. †p 5 0.004, group 2a versus group 2b.
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but that stenting both limbs of bifurcation lesions offers no
advantage over stenting of one arm and balloon angioplasty
with or without atherectomy of the other vessel, and that
stenting of both vessels may be associated with a higher
restenosis rate and the need for more frequent revascular-
ization (31–34). This worse clinical outcome may be hy-
pothesized to be due to overlapped segments of stents and
more trauma during stent deployment, possibly stimulating
the formation of neointimal hyperplasia. Whether stents
specifically designed to treat bifurcation lesions will result in
higher success rates and lower complication rate is yet to be
determined (25).
Antiplatelet therapy. Abciximab, a potent glycoprotein
IIb/IIIa inhibitor of platelet aggregation, reduces ischemic
complications in patients undergoing high and low risk
balloon angioplasty (35–37) and stenting (28). Although the
use of abciximab was shown to be beneficial in bifurcation
lesions treated with balloon angioplasty (38), whether it is
beneficial in combination with coronary stenting or other
percutaneous interventions is unknown. In our study, ab-
ciximab use was not associated with a better short-term or
long-term outcome. However, routine measurements of CK
and CK-MB enzymes were not performed after uncompli-
cated procedures.
Study limitations. The major limitation of our study is its
retrospective, observational design with possible confound-
ing by baseline differences in patient characteristics. Our
study was further limited by the lack of routine angiographic
follow-up. Nonetheless, the ultimate goal of percutaneous
revascularization is relief of angina and avoidance of addi-
tional procedures and cardiac events, and these were closely
monitored in our study.
SUMMARY
This series demonstrates that stents can be deployed with
high success and low complication rates in coronary bifur-
cation lesions. This study suggests that treatment of true
bifurcation lesions with stents in both vessels may not offer
any advantage over stenting of one vessel and balloon
angioplasty and/or atherectomy of the other. Whether
stents specifically designed to treat bifurcation lesions with
or without other adjunctive therapies will result in higher
success rates and lower complication rates has not yet been
determined.
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